Skip to main content
Clinical Trials/NCT02223585
NCT02223585
Completed
Not Applicable

Gut Microbial Response to Well-balanced Diet With Emphasis on Animal or Vegan Protein

Société des Produits Nestlé (SPN)1 site in 1 country40 target enrollmentOctober 2014
ConditionsHealthy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Healthy
Sponsor
Société des Produits Nestlé (SPN)
Enrollment
40
Locations
1
Primary Endpoint
Intra-individual plasma biochemistry response to acute controlled feeding
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Gut microbiota are involved in the regulation of mammalian metabolic pathways through host-microbiota metabolic, signaling, and immune-inflammatory interactions that physiologically connect the gut, liver, brain, and other organs. Correlation of these metabotypes with gut microbial profiles facilitates deciphering inherent host-microbe relationships.

Microbiome sequencing have generated novel insights into the role of gut microbial composition in health and disease, but are limited in addressing the microbial contribution to host metabolism and the gut microbial dysbiosis in disease.

This is an exploratory trial, aiming to examine how gut microbial conditions determine response to dietary challenge by measuring urine, plasma and stool metabolites resulting from metabolism of protein, polyamines and bile acids in combination with stool bacterial composition. The focus of this trial is to evaluate impact of protein based food challenges, based on cross-over design of two diet challenges of animal and vegan protein sources.

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
March 2015
Last Updated
11 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Société des Produits Nestlé (SPN)
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Caucasian
  • Regular bowl movement (at least once every 1-2 days)
  • Between 18 and 55 years old
  • BMI between 18.5 and 27 kg/m2 (inclusive)
  • Willing and able to sign written informed consent prior to trial entry

Exclusion Criteria

  • Clinically relevant digestive, renal or metabolic disease, as determined by the medical (screening) visit and a standard blood chemistry analysis (glucose, total cholesterol, LDL, HDL, triglycerides, Aspartate aminotransferase (ASAT), Alanine aminotransferase (ALAT), gamma glutamyl transferase (Gamma-GT), C reactive protein (CRP), creatinine)
  • Undergoing regular medical treatment, pain-killers accepted, based on the medical questionnaire
  • Special diets: vegetarian, high protein or weight loss program (anamnesis)
  • Pregnancy (anamnesis)
  • Food allergy
  • Participation in a cholesterol management program with functional foods like food supplement enriched in omega-3 fatty acids, dairy products enriched with phytosterols (margarines, yoghurts), evaluated during the medical visit
  • Practicing more than 5 moderated physical activity per week
  • Smoker (anamnesis)
  • Have a high alcohol consumption (more than 2 drinks/day) (anamnesis)
  • Consumption of illicit drugs, (anamnesis)

Outcomes

Primary Outcomes

Intra-individual plasma biochemistry response to acute controlled feeding

Time Frame: Day 1 and 3 of diet challenge 1, 1-Day baseline after challenge 1 washout, Day 1 and 3 of diet challenge 2, 1-Day baseline after challenge 2 washout

To evaluate effect of the dietary challenges (Day 3 vs Day1 of each diet challenge), the global dietary effect (baseline after challenge 2 vs. the baseline after challenge 1, Day 1 of diet challenge 1), stability of the dietary effect (3rd day of each diet challenge vs. baseline after the challenge)

Intra-individual plasma, stools, and urine omics to acute controlled feeding

Time Frame: 3-Day baseline, 3-Day diet challenge 1, 1-Day baseline after challenge 1 washout, 3-Day diet challenge 2, 1-Day baseline after challenge 2 washout

Metabonomics on fasting blood, urine, and stools and microbiota composition by 1. defining individual baseline (3-Day baseline before start of diet challenges); 2. Examining effect of the dietary challenges (3-Day diet challenge vs. Baseline); 3. Examining global dietary effect (baseline after challenge 2 vs. baseline after challenge 1) and stability of dietary effect (3rd day of each diet challenge vs. baseline after the challenge)

Secondary Outcomes

  • Subject's omics adaptation phase to a controlled diet Subject's omics adaptation phase to a controlled diet(3-Day diet challenge 1 and 2)
  • Pairing of gut microbial metabolite to gut microbial composition to generate concept on gut functional system to be followed-up in future studies(3-Day baseline before start of diet challenges, 3-Day diet challenge 1, 1-Day baseline after challenge 1 washout, 3-Day diet challenge 2, 1-Day baseline after challenge 2 washout)
  • Comparison of intra-individual daytime plasma response amongst diets and free living restricted diets(3-Day baseline before start of diet challenges, 3-Day diet challenge 1, 1-Day baseline after challenge 1 washout, 3-Day diet challenge 2, 1-Day baseline after challenge 2 washout)
  • Pairing dietary intake and preferences with subjects response in Omics endpoints(3-Day baseline before start of diet challenges, 3-Day diet challenge 1, 1-Day baseline after challenge 1 washout, 3-Day diet challenge 2, 1-Day baseline after challenge 2 washout)

Study Sites (1)

Loading locations...

Similar Trials